When was Mekonos founded?

Mekonos was founded in 2016 and raised its 1st funding round 4 years after it was founded.

Where is Mekonos located?

Mekonos is headquartered in Palo Alto, United States.

Who is the current CEO of Mekonos?

Steven Banerjee of Mekonos. They have also founded 1 company.

How many employees does Mekonos have?

As of Sep 30, 2026, the latest employee count at Mekonos is 7.

Is Mekonos a funded company?

Mekonos is a funded company, having raised a total of $29.6M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 23, 2020.

When was the latest funding round of Mekonos?

Mekonos' latest funding was a $***** Series A round on Nov 09, 2021, with participation from 10 investors.

Where does Mekonos rank among its competitors?

Mekonos ranks 20th amongst 105 active competitors, of which 36 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was SonoThera, which secured $125M in Jun, 2026.

Who are the top competitors of Mekonos?

Mekonos' top competitors include Genedit, Portal and Chiral Nano. Among them, SonoThera secured the most recent funding round in June, 2026.

Mekonos - 2026 Company Profile, Team, Funding & Competitors

Company Details

Mekonos has is a nanorobotics developing company. The company has developed silicon-based nanorobotic chips for cell engineering. The nanorobots deliver biomolecules to the cells for genetic engineering. The cell therapy procedure can be used for the treatment of cancer.

Website: www.mekonos.com/
Phone Number: +1 **********

Key Metrics

Founded Year

2016

Location

Palo Alto, United States

Stage

Series A

Total Funding

$29.6M in 2 rounds

Latest Funding Round

Series A, Nov 09, 2021, $*****

Investors

Novartis & 16 more

Ranked

20^th among 105 active competitors

Employee Count

7 as on Sep 30, 2026

Similar Companies

Genedit & 131 more

View Mekonos' full profile

Mekonos has raised a total funding of $29.6M over 2 rounds. Its first funding round was on Nov 23, 2020. Its latest funding round was a Series A round on Nov 09, 2021 for $*****. 10 investors participated in its latest round. Mekonos has 17 institutional investors.

Here is the list of recent funding rounds of Mekonos:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 09, 2021	5364291	Series A	9228324	5757414	4285666	5254843
Nov 23, 2020	3726769	Series A	8789650	9525266	Novartis	Hike Ventures & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Mekonos's funding rounds and investors

The founders of Mekonos are Steven Banerjee, Anil Narasimha and Greg Sitters. Steven Banerjee is the CEO of Mekonos.

Here are the details of Mekonos' key team members:

Steven Banerjee: Co-Founder & CEO of Mekonos.
Anil Narasimha: Co-Founder & CSO of Mekonos.
Greg Sitters: Co-Founder of Mekonos.

View details of Mekonos's Founder profiles and Board Members

Mekonos' employee count trend

Mekonos has 7 employees as of Sep 26. Here is Mekonos's employee count trend over the years:

Uncover Mekonos' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Mekonos include Genedit, Portal and Chiral Nano. Here is the list of Top 10 competitors of Mekonos, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Genedit 2016, Berkeley (United States), Series B	Developer of drug delivery system for genetic medicines	$93.5M	IMM Investment, SK & 20 others	65/100
2nd	Portal 2023, Watertown (United States), Seed	Provider of cell engineering and cell analytics across research and clinical applications	$25.7M	NFX, IA Ventures & 7 others	61/100
3rd	Chiral Nano 2022, Zurich (Switzerland), Seed	Provider of nanodevice assembly solutions	$15.8M	Crane Venture Partners, HCVC & 5 others	59/100
4th	Genenta Science 2014, Milan (Italy), Public	Developer of lentivirus-based gene and cell therapies for cancer	$33.6M	Mediobanca, Qianzhan & 4 others	59/100
5th	SonoThera 2022, San Francisco (United States), Series B	Developer of nonviral gene therapies for genetic diseases	$186M	Arch Venture Partners, Vida Ventures & 21 others	57/100
6th	Candel Therapeutics 1999, United States, Public	Developer of viral immunotherapies for the treatment of cancer	$81.6M	PBM Capital, B. Riley Wealth Management & 4 others	57/100
7th	LogicBio 2013, Lexington (United States), Acquired	Developer of viral vectors for the treatment of genetic and infectious diseases	$49M	Arix Bioscience, Pontifax & 6 others	57/100
8th	Recombinetics 2008, New Brighton (United States), Series A	Developer of gene repair and gene-editing technology to create animal models	$66.8M	National Cancer Institute, NIH & 2 others	55/100
9th	ExpreS2ion Biotechnologies 2010, Copenhagen (Denmark), Public	Provider of recombinant protein production using an insect expression platform	-	Modelio Equity, Gemstone Capital & 2 others	52/100
10th	VIVEbiotech 2015, San Sebastian (Spain), Seed	Developer and manufacturer of lentiviral vectors	$3.86M	Inveready, Easo Ventures & 1 others	51/100
20th	Mekonos 2016, Palo Alto (United States), Series A	Developer of silicon-based nanomachine chips	$29.6M	PEAK6, Magnetar & 15 others	43/100